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Aim Transcatheter aortic valve implantationhas becomeanalternative to surgery in higher risk patientswith symptomatic aortic
stenosis. The aim of the ADVANCE study was to evaluate outcomes following implantation of a self-expanding transcath-
eter aortic valve system in a fully monitored, multi-centre ‘real-world’ patient population in highly experienced centres.
Methods
and results
Patientswith severeaortic stenosis at a higher surgical risk inwhom implantationof theCoreValve Systemwasdecidedby
theHeart Teamwere included. Endpointswere a composite ofmajor adverse cardiovascular and cerebrovascular events
(MACCE; all-cause mortality, myocardial infarction, stroke, or reintervention) and mortality at 30 days and 1 year. End-
point-related eventswere independently adjudicatedbasedonValveAcademicResearchConsortiumdefinitions. A total
of 1015 patients [mean logistic EuroSCORE 19.4+12.3% [median (Q1,Q3), 16.0% (10.3, 25.3%)], age 81+6 years]
were enrolled. Implantation of theCoreValve System led to a significant improvement in haemodynamics and an increase
in the effective aortic valveorifice area. At 30 days, theMACCE ratewas 8.0% (95%CI: 6.3–9.7%), all-causemortalitywas
4.5% (3.2–5.8%), cardiovascular mortality was 3.4% (2.3–4.6%), and the rate of stroke was 3.0% (2.0–4.1%). The life-
threatening or disabling bleeding rate was 4.0% (2.8–6.3%). The 12-month rates of MACCE, all-cause mortality, cardio-
vascularmortality, and strokewere 21.2% (18.4–24.1%), 17.9% (15.2–20.5%), 11.7% (9.4–14.1%), and 4.5% (2.9–6.1%),
respectively. The 12-month rates of all-cause mortality were 11.1, 16.5, and 23.6% among patients with a logistic Euro-
SCORE ≤10%, EuroSCORE 10–20%, and EuroSCORE .20% (P, 0.05), respectively.
Conclusion The ADVANCE study demonstrates the safety and effectiveness of the CoreValve Systemwith lowmortality and stroke
rates in higher risk real-world patients with severe aortic stenosis.
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Introduction
Despite advances in cardiac surgeryand lowmortality rates after con-
ventional aortic valve replacement, up to one-third of patients with
symptomatic aortic stenosis are not considered for surgical valve re-
placement, often due to frailty and co-morbidities.1,2
Transcatheter aortic valve implantation (TAVI) enables treatment
of aortic stenosis without open heart surgery.3–15 Recently,
balloon-expandable TAVI has been shown to be superior to the
standard medical therapy for inoperable patients and to be non-
inferior to surgical aortic valve replacement in high-risk patients
with aortic stenosis.16–19 In addition, recent registries including
FRANCE 2 suggest that TAVI using the self-expanding CoreValve
System (Medtronic, Inc., Minneapolis, MN, USA) appears to repre-
sent an alternative option for the treatment of aortic stenosis in
elderly high-risk patients.10,11,13,20 However, most of the published
TAVI registries lack rigorous monitoring and central adjudication of
events, which might lead to an underreporting of events. In addition,
some of the centres contributed data despite the fact that they were
still proctored or on the learning curve.10,11,13,20 Therefore, theCor-
eValve ADVANCE study was designed to evaluate clinical outcomes
following TAVI using the CoreValve System at experienced implant-
ing centres, with adverse event adjudication by an independent Clin-
ical Events Committee according to the original definitions of the
Valve Academic Research Consortium (VARC-1).21
Methods
Patients
ADVANCE (trial registration can be found at http://clinicaltrials.gov/
NCT01074658) is a prospective, multi-centre, fully monitored, non-
randomized study that included 44 sites in 12 countries where the Cor-
eValve System was commercially available. Centres were required to
have an on-site multidisciplinary ‘Heart Team’ comprising at least one
TAVI-experienced interventional cardiologist and one cardiothoracic
surgeon. In addition, the team had to be independent from proctoring,
and have a total TAVI experience of at least 40 cases before joining the
ADVANCE study.
The ethics committee at each study centre approved the investigation-
al protocol. The study was conducted in adherence to theDeclaration of
Helsinki and all the patients were informed of the nature of the study and
provided a signed consent form at least 1 day prior to the CoreValve im-
plantation procedure. Patients were assessed at 30 days and 12 months
following the procedure.
Real-world patients with severe symptomatic aortic stenosis, who
were considered inoperable or at a higher risk for conventional aortic
valve replacement and were anatomically acceptable candidates for
elective treatment with the CoreValve System, were considered for en-
rolment. Only patients currently participating in another trial, patients
who were unwilling or unable (e.g. patients with dementia or those not
able to comprehend the scope of their participation in the study) to
provide written informed consent were excluded from study participa-
tion prior to the TAVI procedure.
Patient enrolment continued until 1000 consented patients had
undergone an implantation procedure.
Study devices and procedures
Detailed device description and implant procedures for the CoreValve
System have been previously described.3,5,22 The method used to
assess the aortic annulus and the size of the access vessels was left to
the discretion of the operator. Implantations were performed with the
18F delivery catheter, later improved by the AccuTrak Stability Layer
(Medtronic). Two valve sizes (26 and 29 mm) were available for an
aortic valve annulus size ranging from 20 to 27 mm. The location (trans-
femoral, direct aortic, and subclavian) and the type of access (surgical cut
down or completely percutaneously) and the type of anaesthesia
(general or deep sedation) were left to the discretion of the Heart
Team. Aortic regurgitation was assessed by angiography after implant-
ation while still in the procedure room. Each centre managed patients
with residual aortic regurgitation (AR) following TAVI per standard
local procedures, which could include snaring, post-dilatation and
implantation of a second CoreValve as a valve in the valve procedure.
Aortic regurgitation after implantation of the CoreValve System was
assessed by transthoracic echocardiography and classified by a local,
experienced echocardiographer according to the recommendation of
the European Association of Echocardiography (none, mild, moderate,
or severe).23Medications, including antiplatelet and anticoagulation ther-
apies, were administered based on hospital-specific procedures.
Study endpoints
The primary endpoint was major adverse cardiac and cerebrovascular
events (MACCE) at30days post-proceduredefined as a compositeof all-
cause mortality, myocardial infarction (Q-wave and non-Q-wave),
stroke, or reintervention. Secondary safety endpoints included the indi-
vidual components of MACCE; cardiovascular mortality, the composite
of stroke and all-cause mortality; and bleeding at 30 days and 12 months.
Secondary endpoints included procedural and device success and
New York Heart Association (NYHA) functional class at discharge,
30days and12months.Device success is definedasmeeting the following
criteria; successful devicedelivery, stable deviceplacement, intact retrieval
of the delivery catheter, and successful device function as assessed imme-
diately post-procedure by angiography including non-compromised flow
in the coronary arteries, no device migration, and a mean AV gradient
,15 mmHg as determined invasively with ≤ grade 2 AR. Procedure
success is defined as device success in the absence of in-hospital MACCE.
Surgical risk factors
The surgical risk for each patientwas evaluated using the Society of Thor-
acic Surgeons (STS) Score and the logistic European System for Cardiac
Operative Risk Evaluation (EuroSCORE). Both instruments are reported
ona scale from0 to100%withhigher values associatedwith a greater risk.
Todeterminewhether patients at low- and high-risk (according to the lo-
gistic EuroSCORE) benefit equally from the TAVI procedure, we divided
the patient population into three groups: logistic EuroSCORE ≤10%
(group 1), .10% but ≤20% (group 2) and .20% (group 3).
Study oversight and data management
The study SteeringCommittee and the sponsor (Medtronic) designed the
protocol and case report forms. Source documentation for all the patients
was fully monitored, and compared with the database. All discrepancies
were resolved prior to locking the database for this report. All primary
endpoint eventswere adjudicatedbyan independentClinical EventsCom-
mittee comprising TAVI-experienced interventional cardiologists and a
cardiac surgeon using the VARC-1 definitions.21 All cerebrovascular
eventswereadjudicatedbyan independentneurologistutilizingall available
relevant sourcedocuments includingneuroimagingandsystematicNation-
al Institute of Health Stroke Scale assessments. A core laboratory (Cardi-
alysis, Rotterdam, The Netherlands) performed systematic review and
assessment of ECGs and procedural angiograms. Data were recorded
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on a standardized electronic case report form and sent to a central data-
base (Merge, Chicago, IL, USA) over the Internet.
Statistical analysis
Categorical variables are reported as counts and percentages with
asymptotic 95% confidence intervals (CIs) and group comparisons are
based on logistic regression models. Continuous variables are reported
as means and standard deviations with 95% CI and group comparisons
basedon general linearmodels. The logistic EuroSCOREandSTSmortal-
ity are summarized using medians and inter-quartile ranges [quartile 1
(Q1) andquartile 3 (Q3)], and comparisons arebasedonnon-parametric
general linear models. Outcomes were calculated using Kaplan–Meier
survival analysis and the log-rank test was used to test for differences
across and between groups. Group pairwise comparison P-values are
presented, if the overall P-values for differences across all three groups
are ,0.05. Freedom-from-event curves were generated using the
Kaplan–Meier method, and the log-rank test was used for comparisons
across the EuroSCORE, AR, and PVL groups. For subjects without an
event, the date of censoring was the latest date of all follow-up visits (in-
cluding study exit) and events (including death).
Univariable Cox regression models were used to evaluate potential
predictors of 12-month mortality. Statistically significant variables with
a P-value ≤0.05 from the univariable analysis were included in the multi-
variable model. Hazard ratios with two-sided 95% CIs were calculated.
All tests were two-sided; however, P-values were not adjusted for mul-
tiple comparisons. For interpretation purposes, the pairwise comparison
P-values should be compared with a Bonferroni-adjusted level of 0.05/
3 ¼ 0.017. All analyses were performed using the SAS software
(Version 9.2, Cary, NC, USA).
Results
Patients
From March 2010 to July 2011, 1015 patients were enrolled in the
ADVANCE study (see Supplementary material online, Figure). The
mean age was 81.1+6.4 years (range 51–96 years) and 51% were
female (Table 1). The baseline peak and mean aortic valve gradients
were 75.9+ 25.1 and 45.6+15.5 mmHg, respectively, and the
mean aortic valve area was 0.7+ 0.3 cm2. The median (Q1, Q3)
logistic EuroSCORE was 16.0% (10.3, 25.3%) and the median (Q1,
Q3) STS score was 5.3% (3.6, 7.8%).
Procedural characteristics
Of the 996 patients implanted, 874 (87.8%) underwent implantation
of the CoreValve System via the femoral approach, and 6 patients
(0.6%) were implanted via the iliac approach for a total iliofemoral
rate of 88.4%. The subclavian approach was used in 95 patients
(9.5%) and the direct aortic approach in 21 (2.1%). Pre-TAVI
balloon valvuloplasty was performed in 906 patients (91.0%).
General anaesthesia was used in 445 of cases (44.7%), and a surgical
cut down was performed to expose the access vessels in 6.3%.The
procedural outcomes are reported in Table 2.
Primary endpoint
The rate of the primary endpoint of MACCEwas 8.0% (95%CI: 6.3–
9.7%) at 30 days and 21.2% (18.4–24.1%) at 12 months (Tables 3
and 4; Figure 1A).
Secondary endpoints
Tables 3 and 4 show all major safety endpoints at 30 days and 12
months. The rate of all-cause mortality was 4.5% (3.2–5.8%) and
17.9% (15.2–20.5%) at 30 days and 12months (Figure 1B); cardiovas-
cular mortality was 3.4% (2.3–4.6%) and 11.7% (9.4–14.1%)
(Figure 1C; Tables 3 and 4), VARC-defined major bleeding rates
were 9.7 and 11.2%, major vascular complications rates were 10.9
and 12.0%, and the rates of acute kidney injury (stage III)22 were 0.4
and 0.6%. The overall rate of stroke was 3.0% (2.0–4.1%) at 30
days and 4.5% (2.9, 6.1%) at 12 months (Figure 1D; Tables 3 and 4);
and the rates of major stroke were 1.2% (0.5–1.9%) and 2.2%
(1.1–3.3%) for the same time periods, respectively. A new perman-
entpacemakerwas implanted in26.3% (23.5–29.1%)of patients at30
days and 29.2% (25.6–32.7%) through 12-month follow-up.
Valve assessment
The CoreValve System was effective at reducing the mean aortic
valve gradient from 45.6+ 15.5 mmHg at baseline to 9.8+
5.4 mmHg at discharge, 9.3+4.8 mmHg at 30 days and 9.5+
5.2 mmHg at 12 months. This was associated with an increase in an
effective orifice area from 0.7+ 0.3 cm2 at baseline to 1.7+
0.5 cm2 at discharge, 1.7+0.5 cm2 at 30 days and 1.7+0.5 cm2 at
12 months.
At discharge, 897 patients had echocardiographic measurements
of total AR or had died (Figure 2A). There was no AR in 172 patients
(19.2%); mild AR was present in 561 patients (62.5%), moderate
AR in 138 (15.4%), severe AR in 2 (0.2%), and 24 patients had died
(2.7%). For the 840 patients alive and with paravalvular AR (PVR)
measurements at discharge (Figure 2B), there was no PVR in 206
patients (23.8%);mild PVRwas present in 504 patients (58.3%),mod-
erate PVR in 128 (14.8%), severe PVR in 2 (0.2%), and 25 patients had
died (2.9%). In addition, there were 422 patients with paired AR data
at discharge, 1 month, 6 months, and 12 months; and 352 patients
with paired PVR data at these time points. Among patients with
paired data, the proportion of patients with moderate total AR
remained fairly constant ranging from 13.7% at discharge; 15.4% at
1 month, 13.3% at 6 months, and 13.5% at 12 months. To determine
change in total AR, therewere 561 patientswith paired total AR data
at discharge and at 12 months. Of these, 138 (24.6%) improved, 337
(60.1%) had no change, and 86 (15.3%) worsened. To determine
change in PVR, there were 510 patients with paired PVR data at dis-
charge and at 12 months. Of these, 136 (26.7%) improved, 289
(56.7%) had no change, and 85 (16.7%) worsened.
Clinical symptoms
At baseline, 35 patients (3.5%) had NYHA class I symptoms, 168
patients (16.9%) were in NYHA class II, 672 patients (67.4%) in
NYHA class III, and 122 patients (12.2%) in NYHA class IV. At
30 days, 84.2% of the followed patients were in NYHA class I or II
and 86.9% at 12 months.
Pre-specified clinical outcomes by logistic EuroSCORE
The higher logistic EuroSCORE in group 3 was driven by the
advanced age of the patients and the presence of more co-
morbidities when compared with group 1 (Table 1). At 30 days,
overall survival and cardiovascular survival did not differ among the
three patient groups (Figure 1B and C; Table 3); however, at 12
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Table 1 Baseline characteristics for all patients and by EuroSCOREa
Assessment All patients (n 5 1015) EuroSCOREb
≤10% (n 5 232)
EuroSCORE >10–20%
(n5 412)
EuroSCORE >20%
(n 5 369)
Overall
P-value
P-valuec P-valued P-valuee
Age, years 81.1+ 6.4 (80.7, 81.5) 77.6+ 6.9 81.7+ 6.1 82.7+ 5.7 ,0.001 ,0.001 ,0.001 0.023
STS mortalityf, %[median (Q1, Q3)] 5.3 (1014) (3.6, 7.8) 3.2 (2.4, 4.6) 5.1 (3.5, 7.2) 7.1 (368) (5.0, 10.1) ,0.001 ,0.001 ,0.001 ,0.001
Logistic EuroSCORE, % [median (Q1, Q3)] 16.0 (1013) (10.3, 25.3) 7.9 (5.8, 9.0) 14.7 (12.3, 17.0) 29.0 (24.4, 37.2) ,0.001 ,0.001 ,0.001 ,0.001
New York Heart Association class III or IV 794/997 (79.6) (77.1, 82.1) 174/226 (77.0) 311/406 (76.6) 307/363 (84.6) 0.013 0.911 0.021 0.006
Diabetes mellitus 314/1003 (31.3) (28.4, 34.2) 81/231 (35.1) 134/405 (33.1) 99/365 (27.1) 0.08 – – –
Coronary artery disease 585/1012 (57.8) (54.8, 60.8) 114/231 (49.4) 226/411 (55.0) 244/368 (66.3) ,0.001 0.170 ,0.001 0.001
Previous myocardial infarction 162/990 (16.4) (14.1, 18.7) 21/228 (9.2) 58/402 (14.4) 81/358 (22.6) ,0.001 0.059 ,0.001 0.004
Previous percutaneous coronary intervention 316/1004 (31.5) (28.6, 34.3) 62/229 (27.1) 120/409 (29.3) 133/364 (36.5) 0.027 0.543 0.017 0.034
Previous median sternotomy 176/1011 (17.4) (15.1, 19.7) 18/231 (7.8) 53 (12.9) 103/366 (28.1) ,0.001 0.051 ,0.001 ,0.001
Previous aortic valve intervention 44/1013 (4.3) (3.1, 5.6) 6/231 (2.6) 12/411 (2.9) 25 (6.8) 0.014 0.812 0.030 0.014
Previous coronary artery bypass grafting 217/1011 (21.5) (18.9, 24.0) 17/231 (7.4) 70/410 (17.1) 128/368 (34.8) ,0.001 ,0.001 ,0.001 ,0.001
Cerebrovascular disease 131/998 (13.1) (11.0, 15.2) 22/229 (9.6) 44/404 (10.9) 65/363 (17.9) 0.004 0.612 0.006 0.006
Aortic aneurysm 24/1008 (2.4) (1.4, 3.3) 4/230 (1.7) 4/409 (1.0) 16/367 (4.4) 0.013 0.413 0.094 0.007
Peripheral vascular disease 198/1006 (19.7) (17.2, 22.1) 33/231 (14.3) 64/409 (15.6) 100/364 (27.5) ,0.001 0.645 ,0.001 ,0.001
Chronic obstructive pulmonary disease 229/1011 (22.7) (20.1, 25.2) 32/231 (13.9) 94/409 (23.0) 101 (27.4) ,0.001 0.006 ,0.001 0.159
Creatinine clearance ,20 mL/min 148/996 (14.9) (12.7, 17.1) 18/229 (7.9) 55/403 (13.6) 73/362 (20.2) ,0.001 0.031 ,0.001 0.016
Atrial fibrillation 334/1006 (33.2) (30.3, 36.1) 63/231 (27.3) 135/409 (33.0) 134/364 (36.8) 0.056 – – –
Permanent pacemaker 131 (12.9) (10.8, 15.0) 22 (9.5) 48 (11.7) 61 (16.5) 0.028 0.397 0.016 0.050
Pulmonary hypertension 128/968 (13.2) (11.1, 15.4) 6/222 (2.7) 33/393 (8.4) 88/351 (25.1) ,0.001 0.008 ,0.001 ,0.001
Additional surgical history
Porcelain aorta 41/1009 (4.1) (2.8, 5.3) 13/231 (5.6) 11/411 (2.7) 17/365 (4.7) 0.159 – – –
Liver cirrhosis 10/1012 (1.0) (0.4, 1.6) 9/231 (3.9) 0/411 (0.0) 1/368 (0.3) 0.002 0.014 0.008 0.459
Right ventricular insufficiency 41/1003 (4.1) (2.9, 5.3) 3/231 (1.3) 14/409 (3.4) 24/361 (6.6) 0.008 0.122 0.006 0.043
Prior thoracic burning sequelae 2/1013 (0.2) (0.0, 0.5) 0/232 (0.0) 1 (0.2) 1/367 (0.3) 0.996 – – –
Echocardiography
Aortic valve area, cm2 0.7+ 0.3 (809) (0.7, 0.7) 0.7+ 0.3 (180) 0.7+ 0.3 (339) 0.7+ 0.3 (288) 0.215 – – –
Peak aortic valve gradient, mmHg 75.9+ 25.1 (881) (74.2, 77.5) 78.7+ 26.2 (197) 78.8+ 25.2 (363) 70.9+ 23.5 (319) ,0.001 0.957 ,0.001 ,0.001
Mean aortic valve gradient, mmHg 45.6+ 15.5 (903) (44.6, 46.6) 47.3+ 15.8 (198) 47.4+ 15.5 (374) 42.6+ 14.9 (329) ,0.001 0.916 ,0.001 ,0.001
Left ventricular ejection fraction, % 53.3+ 13.7 (873) (52.4, 54.2) 57.7+ 11.5 (189) 55.7+ 12.5 (361) 48.0+ 14.4 (322) ,0.001 0.065 ,0.001 ,0.001
LV ejection fraction ,35% 83/873 (9.5) (7.6, 11.5) 6/189 (3.2) 19/361 (5.3) 58/322 (18.0) ,0.001 0.269 ,0.001 ,0.001
Moderate or severe mitral regurgitationg 273/982 (27.8) (25.0, 30.6) 51/222 (23.0) 105/402 (26.1) 117/356 (32.9) 0.022 0.385 0.011 0.042
Moderate or severe tricuspid regurgitationg 177/916 (19.3) (16.8, 21.9) 22/204 (10.8) 60/371 (16.2) 95/339 (28.0) ,0.001 0.079 ,0.001 ,0.001
aData are presented asmeans+ standard deviation (n) or n/total n (%) unless otherwise noted. 95%CIs are presented for data reported for all patients. Reported values are for all patients unless otherwise noted. General linearmodels and logistic
regression models were used to test for overall and group pairwise differences. Pairwise comparison P-values should be compared with a Bonferroni-adjusted alpha level of 0.05/3 ¼ 0.017.
bThe logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) measures patient risk at the time of cardiovascular surgery and is calculated by a logistic regression equation. Scores range from 0 to 100%, with higher scores
indicating greater risk.
cP-values represent comparisons between the EuroSCORE ≤10% and EuroSCORE .10–20% groups.
dP-values represent comparisons between EuroSCORE ≤10% and EuroSCORE .20% groups.
eP-values comparisons between EuroSCORE .10–20% and EuroSCORE .20% groups.
fThe Society of Thoracic score measures risk at the time of cardiovascular surgery on a scale from 0 to 100%, with higher numbers indicating greater risk.
gModerate or severe mitral or tricuspid regurgitation was defined as regurgitation of Grade 3+ or higher.
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Table 2 Procedural characteristics for all patients and by EuroSCOREa
All patients (n 5 996) EuroSCOREb ≤10%
(n5 229)
EuroSCORE >10–20%
(n5 406)
EuroSCORE
>20% (n5 360)
Overall P-valuec
Procedural outcomes
Successful vascular access, delivery and deployment of device,
and successful retrieval of the delivery system
971/996 (97.5) (96.5, 98.5) 223/229 (97.4) 400/406 (98.5) 347/360 (96.4) 0.185
Correct position of one device in the proper anatomical
position at the end of procedured
983/996 (98.7) (98.0, 99.4) 225/229 (98.3) 405/406 (99.8) 352/360 (97.8) 0.113
Mean aortic valve gradient ,20 mmHg 776/807 (96.2) (94.8, 97.5) 178/186 (95.7) 315/330 (95.5) 283/291 (97.3) 0.482
No severe aortic regurgitation 871/873 (99.8) (99.5, 100) 201/201 (100) 354/355 (99.7) 315/316 (99.7) 0.923
Only one valve usedd 956/996 (96.0) (94.8, 97.2) 220/229 (96.1) 390/406 (96.1) 345/360 (95.8) 0.984
Procedural mortalitye 5/996 (0.5) 0.1–0.9% 0/229 (0.0) 2/406 (0.5) 3/360 (0.8) 0.579
Balloon aortic valvuloplasty (BAV)
Pre-implant BAV 906/996 (91.0) (89.2, 92.7) 207/229 (90.4) 379/406 (93.3) 319/360 (88.6) 0.073
Post-implant BAV 235/996 (23.6) (21.0, 26.2) 55/229 (24.0) 100/406 (24.6) 80/360 (22.2) 0.726
Major complications, valve related
Annulus rupture 0/996 (0.0) (0.0, 0.0) 0/229 (0.0) 0/406 (0.0) 0/360 (0.0) –
Valve embolizationd 2/996 (0.2) (0.0, 0.5) 0/229 (0.0) 2/406 (0.5) 0/360 (0.0) 0.551
Conversion to surgical aortic valve replacementf 1/995 (0.1) (0.0, 0.3) 1/229 (0.4) 0/406 (0.0) 0/359 (0.0) 0.460
Coronary compromisedg 1/887 (0.1) (0.0, 0.3) 0/197 (0.0) 0/364 (0.0) 1/325 (0.3) 0.746
aData are presented as n/total n (%) (95% CI).
bThe logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) measures patient risk at the time of cardiovascular surgery and is calculated by a logistic regression equation. Scores range from 0 to 100%, with higher scores
indicating greater risk.
cLogistic regression models were used to test for overall and group pairwise differences. Pairwise comparison P-values should be compared with a Bonferroni-adjusted alpha level of 0.05/3 ¼ 0.017.
dForty patients required use of a second CoreValve bioprosthesis (site-reported); 34 cases were due to malplacement of the first valve, of which 19 were due to valve insufficiency; and 6 cases were due to other reasons. In all cases the second
CoreValve bioprosthesis was successfully implanted in the proper anatomical position.
eTwopatients died fromsevere, diffuse haemorrhagewithout evidenceof vascular perforation at autopsy, 1patient died fromaruptureof the aortic arch, 1patientdiedof acute respiratory failure, and1patientdied secondary to right heart failure as a
result of acquired ventricular septum defect most likely due to the post-dilatation of the Medtronic CoreValve prosthesis with an oversized balloon.
fThis patient had paravalvular regurgitation, which persisted in spite of correct transcatheter heart valve positioning and post-implant BAV. TheAR did not improve, and based on the patient’s clinical status, it was decided to implant a surgical valve.
gPatient had previous coronary artery bypass grafting; compromised flow in native vessel with good flow in grafts.
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Table 3 Outcomes at 30-day follow-up for all patients and by EuroSCOREa
All Patients
(n 5 996)
EuroSCOREb ≤ 10%
(n5 229)
EuroSCORE >10–20%
(n5 406)
EuroSCORE >20%
(n5 360)
Log-rank
P-value
P-valuec P-valued P-valuee
Primary endpoint
MACCE (VARC) 8.0 (6.3, 9.7) 3.5 9.1 9.7 0.017 0.008 0.005 0.812
All-cause mortality 4.5 (3.2, 5.8) 2.6 4.4 5.8 0.193 – – –
Myocardial infarction (VARC) 0.2 (0.0, 0.5) 0.0 0.2 0.3 0.737 – – –
Emergent cardiac surgery or
percutaneous reintervention
1.3 (0.6, 2.1) 0.4 1.3 2.0 0.283 – – –
Stroke (VARC) 3.0 (2.0, 4.1) 1.8 4.2 2.5 0.170 – – –
Additional VARC endpoints
Cardiovascular mortalityf 3.4 (2.3, 4.6) 1.7 3.5 4.5 0.218 – – –
Bleeding 29.0 (26.1, 31.9) 23.2 32.4 28.9 0.056 – – –
Life-threatening or disabling bleeding 4.0 (2.8, 5.3) 3.5 5.0 3.4 0.473 – – –
Major bleeding 9.7 (7.8, 11.6) 7.0 9.7 11.4 0.206 – – –
Minor bleeding 17.4 (15.0, 19.9) 15.8 20.1 15.6 0.208 – – –
Vascular complicationsg 20.7 (18.2, 23.3) 16.2 23.2 20.6 0.118 – – –
Major 10.9 (8.9, 12.8) 7.4 13.1 10.3 0.084 – – –
Minor 10.2 (8.2, 12.1) 9.2 10.1 10.9 0.805 – – –
Stroke or transient ischaemia attack 3.3 (2.2, 4.5) 1.8 5.0 2.5 0.053 – – –
Major stroke 1.2 (0.5, 1.9) 0.9 2.0 0.6 0.173 – – –
Minor stroke 1.8 (1.0, 2.7) 0.9 2.2 2.0 0.458 – – –
Transient ischaemia attack 0.4 (0.0, 0.8) 0.0 1.0 0.0 0.055 – – –
Acute kidney injury—stage III 0.4 (0.0, 0.8) 0.0 0.0 1.1 0.029 ,0.001 0.109 0.033
Additional endpoints
New pacemaker implantation 26.3 (23.5, 29.1) 29.0 26.1 24.8 0.511 – – –
Death from any cause or major stroke 5.1 (3.8, 6.5) 2.6 5.7 6.1 0.146 – – –
MACCE, major adverse cardiovascular and cerebrovascular events. VARC, Valve Academic Research Consortium.
aData presented asKaplan–Meierestimates and 95%CI using thePeto standard error. Log-rank testswere used to test for differences across andbetween groups. Pairwise comparison P-values should becomparedwith aBonferroni-adjusted alpha
level of 0.05/3 ¼ 0.017.
bThe logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) measures patient risk at the time of cardiovascular surgery, and is calculated by a logistic regression equation. Scores range from 0 to 100%, with higher scores
indicating greater risk.
cP-values represent comparisons between the EuroSCORE ≤10% and EuroSCORE .10–20% groups.
dP-values represent comparisons between EuroSCORE≤10% and EuroSCORE .20% groups.
eP-values comparisons between EuroSCORE 10–20% and EuroSCORE .20% groups.
fDeaths from unknown causes were assumed to be deaths from cardiovascular causes.
gWe observed 114 major vascular complication events in ADVANCE: vascular dissection (38), bleeding (22), vascular perforation (14), closure device failure (8), pseudoaneurysm (7), vessel occlusion (5), embolism or distal ischaemia (4), aortic
rupture/dissection (4), access site/retroperitoneal hematoma (4), access site laceration (2), infection requiring surgery (2), access site rupture (1), and access site stenosis (1).
T
reatm
entofaortic
stenosis
w
ith
a
self-expanding
transcatheter
valve
2677
months, a lower risk profile was associated with greater survival
(Table 4).
Predictors of mortality
The predictors of mortality at 12 months are reported in Table 5. In
the multivariable model, besides a low baseline mean gradient, the
occurrence of kidney injury stage III and moderate-to-severe AR at
discharge (Figure 3) was identified as significant independent predic-
tors of mortality at 12 months.
Discussion
The CoreValve ADVANCE study shows that treatment of ‘real-
world’ inoperable or high-risk patients suffering from aortic stenosis
with the CoreValve System—by an experienced TAVI team—is safe
and associated with an improvement in aortic valve function in the
presence of low stroke and mortality rates at 30-day and 12-month
follow-up. Compared with previously reported non-randomized
registries, ADVANCE is a robust study with several unique features
it is the largest, multi-centre, prospective CoreValve TAVI study;
it is fully monitored and the primary endpoint-related events
were adjudicated by an independent Clinical Event Committee
and all cerebrovascular events were assessed by a neurologist
according to VARC-1 definitions; hence, the results are extremely
robust.8,10,11,13,14,20
Overall mortality at 30 days was only 4.5% and therefore, consid-
erably lower than reported for patients treated with the CoreValve
System in the recently published FRANCE 2, the Italian, Belgian,
UK, or German Registries.10,11,13,14,20 This discrepancy cannot be
explained by differences in the risk profile given that the logistic Euro-
SCORE in our study is almost identical to that of the above-
mentioned registries. However, they contain data from early TAVI
experience, in which the inexperience of the operators regarding
patient selection, valve implantation and management of complica-
tions might have driven the early mortality.3–7,13–15,20
Despite excellent procedural success, the rates of vascular and
bleeding complications were higher in ADVANCE when compared
with the above-mentioned registries.10,11,13,14,20 This discrepancy
might be partially explained by the following factors: we applied
VARC-1 definitions to adjudicate ADVANCE study events,
whereas someothers did not. ADVANCEemployed completemon-
itoring and adjudication of events by an independent Clinical Events
Committee, which made it less likely that events were missed.
However, in ADVANCE the higher major bleeding and vascular
Figure 1 Kaplan–Meier time to event analyses for the primary select endpoints for all patients and according to logistic EuroSCORE (≤10%,
.10–20%, and above 20%). (A) The rate of the primary endpoint of major adverse cardiovascular and cerebrovascular events among patients in
the ADVANCE study; (B) rates of death from any cause; (C) rates of death from cardiovascular causes*; (D) rates of stroke*. P-values represent
comparisons among the three EuroSCORE groups using the log-rank test. *Per VARC-1 definitions.21
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complication rates comparedwith other studiesmight be also due to
the fact that themethods to assess the access vessels sizewere left to
the discretion of theoperator.Moreover, the interventionalistswere
asked to follow the instructions for use of the CoreValve, which
requires a minimal vessel diameter of 6 mm. Nevertheless, all of
the commercially available sheaths are bigger than that and have an
outer diameterof at least 7 mm. Especially in patientswith circumfer-
ential calcification, aggressive advancement of the delivery sheath,
which sometimes have a thicker shoulder at the tip, in a vessel that
lost all its elasticitymight have caused dissections, bleedings, and per-
foration. Careful assessment of the vasculature from the site of punc-
ture up to the descending aorta is of utmost importance to prevent
vascular andbleeding complications that are knownto drive themor-
tality. This analysis should notbe limited to the assessmentof vascular
size but should include amount and distribution of calcium as well as
severity of kinking. Nevertheless, the mortality rate at 30 days was
lower in ADVANCE when compared with other registries, which is
consistent with the notion that the experience of the operators in
ADVANCE to recognize and treat those complications might
prevent a rise in early mortality. Moreover, the ADVANCE data
underline that TAVI using the CoreValve System is in fact a remark-
ably safe procedure; there were no cases of annular rupture, only
two cases of valve embolization, one case of conversion to conven-
tional surgery and only one patient with a coronary compromise.
More than half of the implantations were performed with con-
scious sedation.This is indicativeof an improvedperiproceduralman-
agement, where the valve size is selected based on pre-operative CT
or TOEmeasurements, a greater confidence to judge the immediate
results of TAVI only based on angiography and haemodynamics and
to manage complications, even with the patients being awake. The
reduced invasivenessof theprocedure, especially the lackofmechan-
ical ventilation might have its benefits particularly in patients with
severe pre-existing pulmonary disease.
One feared complication of TAVI is stroke, since it is often asso-
ciated with permanent disability. In ADVANCE, stroke rates were
low at 30-day and 12-month follow-up. This is consistent with
results from recent registries, and considerably lower when com-
pared with first in man studies using the CoreValve System and the
data from the PARTNER study.11,16–20 Furthermore, ,50% of
strokes in our study were recognized during the first 2 days. This
finding strongly suggests that procedural factors such as discontinu-
ation of anticoagulants in patients with atrial fibrillation, new onset
atrial fibrillation and athero- and thromboembolism fromthe ascend-
ing aorta or the arch might influence neurological outcome. Further
studies are necessary to address these issues.
In the early daysofTAVI, paravalvular leakwas not attributedmuch
significance.However, it hasbecomeclear thatPVR is associatedwith
reduced late survival.14,18–20 These data are consistent with findings
in the ADVANCE study, in which patients with moderate or severe
PVR at hospital discharge had a cardiovascular mortality that was
almost twice as high at 12 months when compared with those with
none or only mild. All of these data, however, reinforce the need
to reduce or eliminate paravalvular leaks in future device develop-
ment, technological advances, and implant techniques.
The rate of Medtronic CoreValve embolization was 0.2% and
thereforeextremely low.On thecontrary, almost 30%of thepatients
were implanted with a permanent pacemaker at 30 days due to con-
duction abnormalities, which is well in line with recent data from
FRANCE 2 (24.2% after CoreValve System) and the UK (24.4%
after CoreValve System), but lower than that reported in the
German Registry (39%).11,14,20 The reason for the occurrence of
heart block after CoreValve System implantation is probably multi-
factorial involving patient and procedural factors.22 It may well be
that on one hand a deep Medtronic CoreValve position might have
prevented embolizations of the valve into the ascending aorta but
on the other hand lead to a higher rate of permanent pacemaker
implantations. Nevertheless, recent data suggest that changing the
implantation strategy to include a target implant depth of 4–6 mm
for the CoreValve bioprosthesis in the left ventricular outflow tract
might reduce the rate of permanent pacemaker implantation to
10% in the absence of an excessive risk of valve embolization.24
Hence, further studies are necessary to understand the association
between implantation depths, transient and persistent rhythms dis-
orders requiring pacemaker implantation.
Subanalyses such as that of the PARTNER study and theUK Regis-
try suggest that long-term survival after TAVI is a function of the
Figure 2 Aortic regurgitation at discharge, 30 days, 6 and 12
months determined by echocardiography. (A) Total aortic regurgi-
tation by severity; moderate or severe aortic regurgitation was
detected in 140 patients; two of these patients had snaring, which
was successful in one. The other patient received a valve-in-valve
procedure like two other patients, and in 62 out of the 140 patients
a post-dilatation was performed to reduce the aortic regurgitation.
Data are presented for all patients who had echocardiographic
measurement of their aortic regurgitation at each time point and
not as paired data sets for patients who had data at each time
point. (B) Paravalvular regurgitation by severity.
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Table 4 Outcomes at 12-month follow-up for all patients and by EuroSCOREa
All Patients
(n 5 996)
EuroSCOREb ≤10%
(n 5 229)
EuroSCORE >10–20%
(n 5 406)
EuroSCORE >20%
(n5 360)
Log-rank
P-value
P-valuec P-valued P-valuee
Primary outcomes
MACCE (VARC) 21.2 (18.4, 24.1) 12.8 20.6 27.1 ,0.001 0.012 ,0.001 0.047
All-cause mortality 17.9 (15.2, 20.5) 11.1 16.5 23.6 ,0.001 0.064 ,0.001 0.016
Myocardial infarction (VARC) 0.9 (0.2, 1.6) 0.5 1.1 1.0 0.728 – – –
Emergent cardiac surgery or
percutaneous reintervention
1.6 (0.6, 2.5) 0.4 1.3 2.7 0.104 – – –
Stroke (VARC) 4.5 (2.9, 6.1) 3.6 5.1 4.4 0.613 – – –
Additional VARC endpoints
Cardiovascular mortality 11.7 (9.4, 14.1) 5.4 10.7 16.8 ,0.001 0.029 ,0.001 0.019
Bleeding 32.0 (28.4, 35.6) 26.9 34.7 32.3 0.128 – – –
Life-threatening or disabling bleeding 4.9 (3.3, 6.6) 4.0 5.5 4.9 0.684 – – –
Major bleeding 11.2 (8.7, 13.6) 9.4 10.5 13.0 0.307 – – –
Minor bleeding 19.3 (16.3, 22.4) 17.6 21.5 18.1 0.336 – – –
Vascular complications 21.9 (18.7, 25.0) 18.0 24.1 21.5 0.210 – – –
Major 12.0 (9.5, 14.5) 8.9 14.3 11.2 0.119 – – –
Minor 10.3 (7.9, 12.6) 9.6 10.1 10.9 0.879 – – –
Stroke or transient ischaemia attack 6.1 (4.3, 7.9) 5.0 7.4 5.3 0.343 – – –
Major stroke 2.2 (1.1, 3.3) 1.8 2.6 2.1 0.694 – – –
Minor stroke 2.3 (1.1, 3.5) 1.8 2.5 2.3 0.822 – – –
Transient ischaemia attack 1.7 (0.7, 2.7) 1.4 2.5 0.9 0.292 – – –
Acute kidney injury—stage III 0.6 (0.0, 1.2) 0.5 0.0 1.5 0.041 0.196 0.247 0.017
Additional endpoints
New pacemaker implantation 29.2 (25.6, 32.7) 32.9 29.1 26.8 0.338 – – –
Death from any cause or major stroke 18.4 (15.7, 21.1) 11.1 17.5 23.8 ,0.001 0.031 ,0.001 0.036
aDatapresented asKaplan–Meierestimates and 95%CI using thePeto standard error. Log-rank testswere used to test for differences across andbetween groups. Pairwise comparison P-values should becomparedwith aBonferroni-adjusted alpha
level of 0.05/3 ¼ 0.017.
bThe logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) measures patient risk at the time of cardiovascular surgery, and is calculated by a logistic regression equation. Scores range from 0 to 100%, with higher scores
indicating greater risk.
cP-values represent comparisons between the EuroSCORE ≤10% and EuroSCORE .10–20% groups.
dP-values represent comparisons between EuroSCORE ≤10% and EuroSCORE .20% groups.
eP-values comparisons between EuroSCORE .10–20% and EuroSCORE .20% groups. A.Linke
etal.
2680
pre-operative risk profile as indicated by logistic EuroSCORE or the
STS score.11,16–19 To understand the importance of the pre-
operative risk profile on an outcome, we performed a subanalysis
of ADVANCE and divided the study population in three groups
according to the logistic EuroSCORE: ≤10%, .10% and ≤20%
and .20%. At 30 days, the mortality rates among the three groups
did not differ significantly. However, between 30 days and 12
months, the decline in survival was 8.5, 12.1, and 17.8% in those
with a logistic EuroSCORE≤10%,.10% and ≤20%, and.20%, re-
spectively and was of cardiovascular origin in 21, 36, and 40% of the
cases. These data are consistent with the notion that over the long
term, patients with a high baseline logistic EuroSCORE continue to
die from cardiovascular causes despite normalization of the aortic
valve gradient, as well as from non-cardiovascular causes.
Nevertheless, inADVANCEthemortality rateat12months is gen-
erally low (17.9%), including the subset of patients with a logistic
EuroSCORE .20% (mean logistic EuroSCORE 32.3+11.0%,
12-month mortality 23.6%) when compared with other registries
or the PARTNER study (TAVI group; logistic EuroSCORE 26.4+
17.2%, 12-monthmortality, 30.7%: standardmedical therapy; logistic
EuroSCORE 30.4+ 19.1%, 12-month mortality, 49.7%), suggesting
that TAVI using the CoreValve System by an experienced team is
associated with a favourable outcome also in extreme-risk
patients.16–19
The ADVANCE study has limitations: the total number of TAVI
cases performed at the centres was larger than the number of
patients that entered the ADVANCE study and some received
other transcatheter valves. This was due to anatomical factors, deci-
sion of the patients, and the physician. Therefore, like in any other
trial, we cannot exclude that a selection bias may have influenced
the results and we are unable to report data from these patients
treated outside of the ADVANCE study. In addition, the evaluation
of AR by echo post-procedure was performed locally in the
absence of a central echo core laboratory, which might have
induced bias as well. About 25% of the patients had a logistic Euro-
SCORE ,10% but were considered at high operative risk by the
Heart Team consisting of a cardiologist and cardiac surgeon. It is
highly likely that factors such as frailty, the presence of porcelain
aorta or hostile chest—all factors not captured by the logistic Euro-
SCORE—convinced the Heart Team to propose a TAVI in these
patients. This is supported by the finding that the presence of liver
disease was more frequent in the group of patients with the lowest
EuroSCORE. However, future trials such as Surgical Replacement
and Transcatheter Aortic Valve Implantation (SURTAVI, Clinical-
Trials.gov identifier; NCT01586910) are required to assess the
results of TAVI in an intermediate risk cohort of patients with symp-
tomatic aortic stenosis. However, ADVANCEwas not a randomized
trial andcaseswereselectedbyaHeartTeam, andwhile comparisons
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Predictors of all-cause mortality at 12 months
Variable Alive (n5 822) Dead (n5 174) Univariablemodel P-value Multivariable
model
P-value
Male 396/822 (48.2) 95/174 (54.6) 1.25 (0.93, 1.68) 0.146
Diabetes mellitus 247/815 (30.3) 59/170 (34.7) 1.18 (0.86, 1.61) 0.316
Coronary artery disease 465/819 (56.8) 109/174 (62.6) 1.25 (0.92, 1.70) 0.159
Previous myocardial infarction 285/822 (34.7) 65/174 (37.4) 1.13 (0.83, 1.53) 0.448
Previouspercutaneouscoronary intervention 248/813 (30.5) 62/173 (35.8) 1.24 (0.91, 1.69) 0.179
Previous coronary artery bypass 176/818 (21.5) 35/174 (20.1) 0.92 (0.63, 1.33) 0.644
Cerebrovascular disease 25/822 (3.0) 18/174 (10.3) 3.02 (1.86, 4.93) ,0.001 1.84 (0.87, 3.85) 0.11
Peripheral vascular disease 152/815 (18.7) 44/172 (25.6) 1.43 (1.02, 2.02) 0.039 1.34 (0.86, 2.08) 0.20
Chronic obstructive pulmonary disease 178/818 (21.8) 48/174 (27.6) 1.31 (0.94, 1.83) 0.112
Creatinine (mg/dL) 1.2+0.7 (815) 1.5+0.9 (173) 1.25 (1.12, 1.39) ,0.001 1.15 (0.99, 1.33) 0.06
Baseline New York Heart Association III/IV 644/822 (78.3) 139/174 (79.9) 1.09 (0.75, 1.58) 0.655
Logistic EuroSCORE 18.6+11.7 (822) 22.8+14.2 (173) 1.02 (1.01, 1.03) ,0.001 1.01 (1.00, 1.03) 0.09
Baseline left ventricular ejection fraction
≤50%
255/707 (36.1) 67/148 (45.3) 1.44 (1.04, 1.99) 0.028 1.11 (0.72, 1.70) 0.64
Baseline mean aortic valve gradient 46.3+15.9 (732) 42.2+13.3 (153) 0.98 (0.97, 0.99) 0.003 0.99 (0.97, 1.00) 0.03
Transfemoral 730/822 (88.8) 150/174 (86.2) 0.81 (0.52, 1.24) 0.326
Major vascular complication 89/822 (10.8) 32/174 (18.4) 1.75 (1.19, 2.57) 0.004 1.00 (0.54, 1.85) 0.99
Minor vascular complication 87/822 (10.6) 15/174 (8.6) 0.81 (0.48, 1.38) 0.447
Life-threatening bleeding 31/822 (3.8) 17/174 (9.8) 2.57 (1.56, 4.24) ,0.001 2.04 (0.93, 4.44) 0.07
Major bleeding 89/822 (10.8) 24/174 (13.8) 1.25 (0.81, 1.93) 0.302
Minor bleeding 166/822 (20.2) 26/174 (14.9) 0.72 (0.47, 1.09) 0.115
Acute kidney injury (stage III) 0/822 (0.0) 6/174 (3.4) 10.97 (4.83, 24.92) ,0.001 9.75 (3.68, 25.84) ,0.001
New pacemaker 242/822 (29.4) 47/174 (27.0) 0.89 (0.64, 1.24) 0.482
Discharge aortic regurgitation moderate/
severe
111/743 (14.9) 29/130 (22.3) 1.62 (1.07, 2.44) 0.023 1.63 (1.03, 2.59) 0.04
All data reported as n/total n (%), means+ standard deviation (n) and hazard ratios (95%CI). Univariable predictors significant at P ≤ 0.05 were included in themultivariable model.
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to randomized trials may not be valid, this study does reflect expert
clinical practice in real-world patients.
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Supplementary material is available at European Heart Journal online.
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Valve-in-valve transfemoral TAVR: Sapien 3 valve within a failed core valve
bioprosthesis
Anupama Shivaraju*, Ilka Ott, Adnan Kastrati, and Albert M. Kasel
Deutsches Herzzentrum, Technische Universita¨t, Lazarettstr. 36, 80636 Munich, Germany
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A 76-year-old woman with a medical history of
stroke, hypertension, and paroxysmal atrial fibril-
lation presented with symptoms of acute decom-
pensated heart failure 1.5 years after undergoing
transcatheter aortic valve replacement (TAVR)
with a bioprosthetic Medtronic Core Valve
(CoV) for severe aortic stenosis. Her echocardio-
gram showed an ejection fraction of 33% with
severe paravalvular aortic insufficiency (AI).
The longitudial CT image (Panel A) shows a
29 mm CoV implanted 15 mm below the
annulus (red line); Therefore, the CoV skirt does
not cover the annulus along the left coronary
cusp region (arrow). The CoV skirt is 3 mm
below the annulus and 12 mm from the distal
edge (Panel B). The transverse CT image shows
an inadquately deployed CoV (Panel C). The
high degree AI jet through the paravalvular
gap (arrow) was also noted on angiography
(Panel D). A 26 mm Sapien 3 (S3) valve was
deployed with placement of its outer skirt above
the CoV gap (Panel E). The S3 valve was placed
slightly below the left main (LM) to avoid a
double stent layer at the LM coronary ostium
(Panel F). The high degree, eccentric AI (Panel G) as noted on echo before the S3 valve implant was successfully reduced to an insignificant
AI (Panel H) post-procedure.
The feasibility of valve-in-valve (VIV) TAVR for the treatment of failed AV prosthesis has been described before. Here, for the first time,
we demonstrate a sussessful VIV TAVR procedure using the new generation Sapien 3 valve.
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